🔍

HCG - Health.Global

📊 NSE: HCG 🏢 Healthcare 📅 Last Updated: 12/13/2025 22:51

📢 Recent Corporate Announcements

HCG Submits Quarterly Compliance Certificate under SEBI Regulation 74(5)

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 22 Apr 2026, 10:42 AM

Healthcare Global Enterprises Limited (HCG) has submitted its compliance certificate for the quarter ended March 31, 2026, as required by SEBI (Depositories and Participants) Regulations. The certificate, issued by KFin Technologies, confirms that all share dematerialization requests were processed within the mandatory 15-day period. It also verifies that physical share certificates were mutilated and cancelled after the process. This is a standard procedural filing to ensure the integrity of electronic shareholding records.

Compliance certificate submitted for the quarter ending March 31, 2026.
Confirmation that demat requests were processed within 15 days of receipt.
Physical security certificates were mutilated and cancelled after due verification.
KFin Technologies Limited served as the Registrar and Share Transfer Agent (RTA).

💡 No action is required from investors as this is a routine regulatory filing confirming standard operational compliance.

HCG Completes Acquisition of Additional 34% Stake in Vizag Hospital for ₹154.5 Crore

🟢 POSITIVE ⭐ 8/10

M&A 📅 13 Apr 2026, 07:55 PM

Healthcare Global Enterprises (HCG) has successfully completed the acquisition of an additional 34% equity stake in Vizag Hospital and Cancer Research Centre Private Limited. The company acquired 1,93,441 equity shares for a total cash consideration of approximately ₹154.5 crore. This transaction increases HCG's total ownership in the Vizag-based entity to 85%. This move is part of a staged acquisition strategy initiated in June 2024 to consolidate its presence in the oncology healthcare market.

Acquired 1,93,441 equity shares representing a 34% stake in Vizag Hospital.
Total purchase consideration for this tranche amounts to INR 154.50 crore.
HCG's aggregate ownership in Vizag Hospital and Cancer Research Centre now stands at 85%.
The acquisition follows the Share Purchase Agreement (SPA) and Shareholders' Agreement (SHA) initiated in June 2024.

💡 Investors should view this as a positive consolidation of a key regional asset, which likely improves HCG's control and financial integration of the Vizag facility. Monitor the company's upcoming quarterly results for the impact of full consolidation of this entity's performance.

HCG Announces Trading Window Closure from April 1, 2026, for Q4 and FY26 Financial Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 31 Mar 2026, 06:10 PM

Healthcare Global Enterprises Limited (HCG) has announced the closure of its trading window starting April 1, 2026, in compliance with SEBI Insider Trading regulations. This closure is ahead of the declaration of the company's standalone and consolidated financial results for the quarter and financial year ending March 31, 2026. The window will remain closed for all designated persons until 48 hours after the results are made public. This is a standard regulatory procedure followed by listed Indian companies before every earnings release.

Trading window closure effective from Wednesday, April 1, 2026
Closure pertains to the financial results for the quarter and year ending March 31, 2026
Window to reopen 48 hours after the official declaration of financial results
Restriction applies to all designated persons and insiders as per SEBI PIT Regulations
Compliance covers both standalone and consolidated financial statements

💡 No immediate action is required as this is a routine regulatory filing. Investors should monitor for the upcoming announcement of the specific date for the Q4 and FY26 earnings release.

HCG to Invest ₹253.66 Cr in Subsidiaries; Increasing Vizag Hospital Stake to 85%

🟢 POSITIVE ⭐ 8/10

M&A 📅 30 Mar 2026, 03:58 PM

HCG's board has approved a total investment of ₹253.66 crore across two key subsidiaries to consolidate its position and optimize its balance sheet. The company will spend ₹155.66 crore to increase its stake in Vizag Hospital from 51% to 85%, a profitable unit that recorded a PAT of ₹18.79 crore in FY25. Additionally, ₹98 crore will be infused into its Nagpur-based wholly-owned subsidiary, HCG NCHRI, to prepay or repay outstanding debt. These investments are funded via a previously approved rights issue and are expected to be completed in Q1 FY2027.

Acquisition of an additional 34% stake in Vizag Hospital for ₹155.66 crore, increasing total ownership to 85%.
Investment of ₹98 crore in HCG NCHRI (Nagpur) specifically for debt reduction and pre-payment.
Vizag Hospital reported strong financials with FY25 revenue of ₹110.14 crore and PAT of ₹18.79 crore.
HCG NCHRI (Nagpur) demonstrated significant growth, with revenue rising from ₹51.40 crore in FY23 to ₹89.80 crore in FY25.
Funding for both transactions is sourced from the rights issue approved by the company in February 2026.

💡 Investors should view this as a strategic move to consolidate ownership in profitable regional hubs and improve consolidated margins by reducing subsidiary-level debt. The increased stake in the high-growth Vizag unit is likely to be EPS accretive in the long term.

HCG Allots 82.94 Lakh Equity Shares at ₹512/Share via Rights Issue

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 27 Mar 2026, 10:24 PM

HealthCare Global Enterprises Limited (HCG) has completed the allotment of 82,94,566 equity shares following its recently concluded rights issue. The shares were allotted at a price of ₹512 per share, including a premium of ₹502, to eligible shareholders and renouncees. This issuance has increased the company's total paid-up equity share capital from ₹141.01 crore to ₹149.30 crore. The successful completion of this fundraise strengthens the company's capital base for its ongoing operations and strategic initiatives.

Allotment of 82,94,566 fully paid-up equity shares of face value ₹10 each
Issue price set at ₹512 per share, including a premium of ₹502
Total paid-up equity shares increased from 14,10,07,637 to 14,93,02,203
Paid-up equity share capital rose from ₹141,00,76,370 to ₹149,30,22,030
The rights issue was open for subscription from March 11, 2026, to March 25, 2026

💡 Investors should account for the minor equity dilution of approximately 5.8% in the total share capital. However, the successful capital infusion at a significant premium reflects well on the company's ability to raise funds for growth.

HCG Winds Up Non-Operating Indirect Subsidiary in Tanzania

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Mar 2026, 06:09 PM

Healthcare Global Enterprises Limited (HCG) has announced the formal winding up of its indirect subsidiary, Healthcare Global (Tanzania) Private Limited, effective March 02, 2026. The subsidiary was a non-operating entity and had zero contribution to the company's consolidated turnover, income, or net worth during the last financial year. This move appears to be a routine administrative cleanup of dormant international structures. There is no financial impact or consideration involved in this liquidation process.

Healthcare Global (Tanzania) Private Limited wound up effective March 02, 2026.
The subsidiary contributed 0% to the company's consolidated turnover and net worth.
No financial consideration was received as the entity was non-operational.
Formal notification of the winding up was received by the parent company on March 26, 2026.

💡 No action is required from investors as this is a routine corporate restructuring of a dormant unit with no impact on the company's financials or operations.

HCG Announces ₹424.68 Crore Rights Issue at ₹512 Per Share

🟡 NEUTRAL ⭐ 8/10

FUNDRAISE 📅 25 Feb 2026, 12:58 AM

Healthcare Global Enterprises Limited (HCG) is launching a rights issue to raise up to ₹424.68 crore through the issuance of 8.29 million equity shares. The issue price is set at ₹512 per share, and the rights ratio is 1 share for every 17 shares held as of the record date, March 2, 2026. The subscription period is scheduled from March 11 to March 25, 2026, with the last date for on-market renunciation being March 20, 2026.

Total fundraise of ₹42,468.18 lakhs (approx ₹424.68 crore) via 8.29 million shares.
Rights ratio of 1:17 for eligible shareholders as of the March 2, 2026 record date.
Issue price fixed at ₹512 per share, including a premium of ₹502.
Subscription window opens March 11 and closes March 25, 2026.

💡 Investors should compare the ₹512 issue price with the prevailing market price; if the market price is higher, they should consider subscribing or selling their rights entitlements by March 20.

HCG Announces ₹424.68 Cr Rights Issue at ₹512/Share; Record Date March 2, 2026

🟡 NEUTRAL ⭐ 8/10

FUNDRAISE 📅 24 Feb 2026, 08:10 PM

Healthcare Global Enterprises (HCG) has finalized the terms for its rights issue to raise approximately ₹424.68 crore. The company will issue 82,94,566 equity shares at a price of ₹512 per share, which includes a premium of ₹502. The rights entitlement ratio is fixed at 1:17, meaning eligible shareholders can purchase one new share for every 17 shares held as of the record date, March 2, 2026. The issue is scheduled to open on March 11 and close on March 25, 2026.

Total rights issue size of ₹42,468.18 Lakhs (approx ₹424.68 Cr) for 82,94,566 shares.
Rights issue price set at ₹512 per share, a significant premium over the ₹10 face value.
Entitlement ratio of 1 equity share for every 17 shares held as of March 2, 2026.
Subscription period runs from March 11, 2026, to March 25, 2026.
Post-issue share capital will increase to 14,93,02,203 equity shares assuming full subscription.

💡 Existing shareholders should decide whether to exercise their rights, renounce them by selling the entitlements on the exchange, or let them lapse. To avoid dilution of value, shareholders should either subscribe to the issue or sell their Rights Entitlements (REs) during the trading window from March 11 to March 20.

HCG to Raise ₹424.68 Crore via Rights Issue at ₹512 per Share; Ratio 1:17

🟡 NEUTRAL ⭐ 8/10

FUNDRAISE 📅 24 Feb 2026, 08:06 PM

Healthcare Global Enterprises Limited (HCG) has approved a rights issue to raise approximately ₹424.68 crore by issuing 82,94,566 equity shares. The issue is priced at ₹512 per share, and the rights entitlement ratio is fixed at 1:17 for shareholders holding stock as of the record date, March 02, 2026. The subscription period will run from March 11 to March 25, 2026, with the option for shareholders to renounce their rights on the market until March 20, 2026. This move will increase the company's total outstanding equity shares from 14.10 crore to 14.93 crore upon full subscription.

Rights issue size of ₹424.68 crore at an issue price of ₹512 per share.
Rights entitlement ratio set at 1 equity share for every 17 shares held.
Record date for eligibility is March 02, 2026, with the issue opening on March 11, 2026.
On-market renunciation period ends on March 20, 2026.
Total equity base to expand by approximately 5.88% to 14.93 crore shares.

💡 Investors should compare the ₹512 issue price with the current market price to determine the attractiveness of the offer. Those not wishing to subscribe should sell their Rights Entitlements (REs) on the exchange before March 20 to avoid the loss of value from the rights dilution.

HCG to Raise ₹424.68 Cr via Rights Issue at ₹512 per Share; Ratio 1:17

🟡 NEUTRAL ⭐ 8/10

FUNDRAISE 📅 24 Feb 2026, 08:01 PM

Healthcare Global Enterprises Limited (HCG) has finalized terms for its ₹424.68 crore rights issue. Shareholders holding shares on the record date of March 02, 2026, are eligible to apply for 1 new share for every 17 shares held. The issue price is set at ₹512 per share, which includes a premium of ₹502. The subscription window opens on March 11 and closes on March 25, 2026.

Rights issue of 82,94,566 shares to raise approximately ₹424.68 crore.
Issue price fixed at ₹512 per share with an entitlement ratio of 1:17.
Record date for eligibility is March 02, 2026, with the issue closing on March 25, 2026.
Post-issue equity capital to increase to 14.93 crore shares from 14.10 crore shares.

💡 Investors should monitor the stock price relative to the ₹512 offer price; if the market price remains significantly higher, exercising rights or selling entitlements is advisable. Ensure action is taken before the March 20 renunciation deadline to prevent loss of value.

HCG Board Approves Rights Issue of Up to ₹425 Crores

🔵 WATCH ⭐ 7/10

FUNDRAISE 📅 17 Feb 2026, 07:45 PM

The Board of HealthCare Global Enterprises Limited (HCG) has approved a proposal to raise capital up to ₹42,500 Lakhs (₹425 Crores) through a rights issue of equity shares. The issuance will be offered to eligible shareholders as of a record date that is yet to be determined. Key details such as the issue price, rights entitlement ratio, and timing will be finalized by a dedicated Rights Issue Committee. This move indicates a significant capital infusion, likely aimed at strengthening the company's financial position or funding future growth initiatives.

Board approved issuance of equity shares for an amount not exceeding ₹42,500 Lakhs.
The fundraise will be conducted via a rights issue to existing eligible shareholders.
Equity shares will have a face value of ₹10 each and will be fully paid-up.
Specific terms including issue price and entitlement ratio are to be determined by the Rights Issue Committee.
The announcement follows a board meeting held on February 17, 2026, which concluded at 7:25 p.m.

💡 Investors should monitor upcoming announcements regarding the rights price and entitlement ratio to evaluate the potential dilution and the attractiveness of the offer. The stock's reaction will likely depend on whether the funds are earmarked for high-growth expansions or debt reduction.

HCG Board Approves Rights Issue to Raise Up to ₹425 Crores

🔵 WATCH ⭐ 8/10

FUNDRAISE 📅 17 Feb 2026, 07:41 PM

Healthcare Global Enterprises Limited (HCG) has approved a fundraise of up to ₹425 Crores through a rights issue of equity shares. The board meeting held on February 17, 2026, authorized the issuance to eligible shareholders as of a future record date. Details regarding the issue price, entitlement ratio, and timing will be finalized by a dedicated committee. This move is aimed at strengthening the company's capital base for potential expansion or debt management.

Board approved fundraise not exceeding ₹42,500 Lakhs (₹425 Crores) via a rights issue.
The issue involves fully paid-up equity shares with a face value of ₹10 each.
Specific terms like issue price, entitlement ratio, and record date are yet to be determined by the Rights Issue Committee.
The capital raise is subject to necessary regulatory and statutory approvals.

💡 Monitor for the announcement of the rights price and entitlement ratio to evaluate the attractiveness of the offer. Long-term investors should assess the company's planned use of proceeds for growth versus debt reduction.

HCG Q3 FY26 Revenue Rises 13.4% to ₹633 Cr; EBITDA Margins Expand to 17.5%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 09:37 PM

Healthcare Global Enterprises (HCG) reported a steady Q3 FY26 with revenues growing 13.4% YoY to INR 633 crore, despite seasonal softness. Adjusted EBITDA grew 20% YoY to INR 111 crore, with margins expanding by 100 bps to 17.5% due to better operating leverage and digital efficiency. The company is expanding its footprint with a new 120-bed facility in North Bangalore expected in Q4 FY26 and a 60-bed brownfield expansion in Cuttack by FY27. 9M FY26 performance remains strong with a 16% revenue growth and a pre-tax ROCE of 13.3%.

Q3 FY26 Revenue increased 13.4% YoY to INR 633 crore, while 9M FY26 Revenue reached INR 1,893 crore.
Adjusted EBITDA for the quarter grew 20% YoY to INR 111 crore, with margins improving to 17.5% from 16.5%.
Digital revenue saw a significant 26% YoY growth, with the mobile app scaling 4.5x to contribute 13% of digital sales.
Expansion plans include the 120-bed North Bangalore facility launching in Q4 FY26 and 60 additional beds in Cuttack by FY27.
West cluster led regional growth at 17% YoY, while South cluster grew 9% despite temporary state-scheme disruptions in Andhra Pradesh.

💡 Investors should monitor the successful commissioning and ramp-up of the North Bangalore facility in Q4 FY26 as a key growth catalyst. The sustained margin expansion and improving ROCE (13.3%) suggest strong operational execution in a specialized oncology market.

HCG Releases Audio Recording of Q3 FY2026 Earnings Call

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Feb 2026, 04:12 PM

Healthcare Global Enterprises Limited (HCG) has officially released the audio recording of its earnings call held on February 09, 2026. The call focused on the company's unaudited standalone and consolidated financial results for the quarter and nine-month period ending December 31, 2025. This disclosure is part of the company's regulatory compliance under SEBI Listing Obligations and Disclosure Requirements. Investors can now access the full management commentary and Q&A session via the company's investor relations website.

Earnings call conducted on February 09, 2026, following the Q3 FY2026 results announcement.
Covers financial performance for the nine-month period ended December 31, 2025.
Compliance with Regulation 46(2)(oa) of SEBI LODR Regulations.
Recording link made available on the official HCG oncology investor relations portal.

💡 Investors should listen to the recording to gain insights into management's outlook on patient volumes and margin trends. No immediate action is required as this is a routine regulatory filing.

HCG Q3FY26 Results: Revenue Up 13% YoY to ₹6,331 Mn, Adjusted EBITDA Jumps 20%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 06 Feb 2026, 10:51 PM

Healthcare Global Enterprises (HCG) reported a strong Q3FY26 with consolidated revenue growing 13% YoY to ₹6,331 Mn. The company's Adjusted EBITDA rose 20% to ₹1,108 Mn, driven by a 98 bps margin expansion to 17.5% due to operating leverage. Adjusted PAT saw a significant increase to ₹70 Mn compared to ₹6 Mn in the previous year's quarter. For the nine-month period, revenue and EBITDA both showed robust growth of 16% and 20% respectively, reflecting steady execution across its oncology network.

Consolidated Revenue for Q3FY26 grew by 13% YoY to ₹6,331 Mn.
Adjusted EBITDA increased by 20% YoY to ₹1,108 Mn with margins expanding 98 bps to 17.5%.
Adjusted PAT (Post IND AS) surged to ₹70 Mn in Q3FY26 from ₹6 Mn in Q3FY25.
9M FY26 Revenue reached ₹18,931 Mn, a 16% increase over the previous year.
9M FY26 Adjusted EBITDA stood at ₹3,458 Mn, up 20% YoY with margins at 18.3%.

💡 Investors should take note of the consistent margin expansion and strong EBITDA growth, which demonstrate the scalability of HCG's specialized oncology model. The significant improvement in bottom-line profitability makes it a positive outlook for long-term healthcare portfolios.

View All HCG Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated operating income grew 12.8% YoY to INR 1,912.1 Cr in FY2024 from INR 1,694.4 Cr in FY2023. The Milann (fertility) segment saw a significant revenue increase from INR 9.1 Cr in FY2023 to INR 43.3 Cr in FY2025, representing a 119% CAGR. International operations (Kenya) contributed INR 57.8 Cr in FY2025, though this declined at a -4% CAGR from FY2020 levels of INR 70.1 Cr.

Geographic Revenue Split

Based on FY2025 revenue potential, the West region is the largest contributor at INR 989.9 Cr (44.5%), followed by the South region at INR 874.6 Cr (39.3%), and the East region at INR 254.8 Cr (11.5%). The company operates in 19 markets and holds a leading position in 16 cities.

Profitability Margins

Profit After Tax (PAT) margin improved from 1.0% (INR 17.6 Cr) in FY2023 to 2.1% (INR 40.9 Cr) in FY2024, and further to 2.5% (INR 41.2 Cr) in 9M FY2025. Operating margins (OPBDIT/OI) remained stable at 17.2% in 9M FY2025 compared to 17.3% in FY2024.

EBITDA Margin

Consolidated EBITDA margin stood at 17.2% for 9M FY2025, with H1 FY2025 margins specifically improving to ~19%. Mature centers generating >INR 100 Mn monthly revenue demonstrate a strong EBITDA margin profile of 25%+, while mid-tier centers (INR 50-100 Mn) operate at 20% margins.

Capital Expenditure

Total capital expenditure over the last five years reached INR 659.4 Cr, comprising INR 353.3 Cr for maintenance, INR 186.1 Cr for bed and equipment expansion, and INR 120 Cr for shifting the Ahmedabad Center of Excellence (COE).

Credit Rating & Borrowing

The company maintains an [ICRA]A+ (Stable) rating for long-term fund-based facilities (INR 655.09 Cr) and [ICRA]A1 for short-term non-fund based limits (INR 43.52 Cr). Interest coverage ratio was 3.0x in FY2024.

⚙️ Operational Drivers

Raw Materials

Medical consumables, pharmaceutical drugs (chemotherapy agents), and surgical implants represent the primary operational costs, though specific percentage breakdowns are not disclosed.

Capacity Expansion

Current capacity includes 2,500 beds and the largest LINAC installation base in India with 38 units. Planned expansion includes the shifting and upgrading of the Ahmedabad COE (INR 120 Cr) and the integration of the Vizag acquisition (INR 206 Cr first tranche).

Raw Material Costs

Procurement is identified as a key lever for margin improvement over a 4-5 year journey, aiming to bring all centers to mature-level margins.

Manufacturing Efficiency

Average Occupancy Rate (AOR) was 65.6% in H1 FY2025. Average Revenue Per Occupied Bed (ARPOB) increased to INR 45,188 in H1 FY2025, a significant rise from the FY2020 level of INR 19,901 (15% CAGR).

📈 Strategic Growth

Expected Growth Rate

18%

Growth Strategy

The strategy focuses on migrating 11 centers currently in the INR 50-100 Mn monthly revenue bucket (20% margin) into the >INR 100 Mn bucket (25%+ margin) through volume growth in the high teens. This is supported by KKR's acquisition of a 54-77% stake, providing access to global expertise and long-term capital for accretive acquisitions like Vizag (INR 206 Cr) and Indore (INR 45 Cr).

Products & Services

Radiation oncology, surgical oncology, medical oncology, PET-CT diagnostics, and IVF/fertility treatments (Milann).

Brand Portfolio

HCG (Healthcare Global), Milann.

New Products/Services

Expansion of sub-specialization in oncology and adoption of advanced treatment techniques; Milann fertility centers are expected to contribute more significantly following a 119% revenue CAGR.

Market Expansion

Recent acquisitions in Vizag (INR 206 Cr) and Indore (INR 45 Cr) to consolidate leadership in Tier 1 and Tier 2 cities.

Market Share & Ranking

Market leader in 16 out of 19 cities of operation; possesses 3x the LINAC base of its closest competitor.

Strategic Alliances

Definitive agreement signed with KKR Group to become the largest shareholder (54-77% stake), replacing CVC Group (Aceso Company Pte Ltd).

🌍 External Factors

Industry Trends

The industry is shifting toward comprehensive, specialized cancer centers. HCG is positioned as a leader with 38 LINACs and 400+ oncologists, benefiting from an 18% CAGR in mid-tier center revenue as they mature.

Competitive Landscape

Faces competition from multi-specialty hospital chains, though HCG's specialized focus provides a 'right to win' in oncology.

Competitive Moat

Durable moat built on 'clinical density' (2x oncologists vs competitors) and 'technology leadership' (3x LINAC base). This scale creates a high barrier to entry and attracts top oncology talent.

Macro Economic Sensitivity

High sensitivity to cancer incidence rates in India and the demand-supply gap for high-quality oncology care.

Consumer Behavior

Increasing preference for specialized oncology platforms over general hospitals for complex cancer treatments.

Geopolitical Risks

Operations in Kenya (HCG CCK Cancer Centre) expose the company to regional political and economic stability risks.

⚖️ Regulatory & Governance

Industry Regulations

Subject to restrictive pricing regulations by central and state governments (e.g., NPPA drug price caps) and clinical establishment standards.

Legal Contingencies

The transfer of the oncology business of HCG NCHRI Oncology LLP to the company was carried out at other than fair value to comply with specific laws; no other major pending court case values were disclosed.

⚠️ Risk Analysis

Key Uncertainties

Regulatory intervention in healthcare pricing (high impact), integration risks of new acquisitions in Vizag and Indore, and the transition of control to KKR.